Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Neuroendocrine Prostate Cancer May Not Mean the End of PSMA
/in Retrospective studies/by MaxProstate cancer that develops neuroendocrine features is commonly associated with loss of androgen-receptor dependence and reduced PSMA expression, potentially making PSMA-targeted treatments less useful. A new dual-tracer imaging study suggests that the reality may be considerably more complicated. Researchers retrospectively examined eight men with metastatic castration-resistant prostate cancer who were suspected of developing treatment-emergent neuroendocrine […]
PET-Guided Radiotherapy Shows Lasting Control of Recurrent Prostate Cancer
/in Retrospective studies/by MaxA new retrospective study with a 10-year follow-up suggests that some men with prostate cancer recurring only in lymph nodes may achieve prolonged disease control using PET-directed radiotherapy combined with temporary androgen deprivation therapy (ADT). The retrospective study included 93 men with hormone-sensitive prostate cancer that had returned in pelvic and/or para-aortic lymph nodes after […]
Phase 1 Trial for SNV1521 PARP1 Inhibitor in mCRPC aka mAPMR Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxA next-generation PARP inhibitor called SNV1521 is showing early signs of activity in advanced prostate cancer, while potentially causing less bone-marrow toxicity than existing PARP drugs. SNV1521 is an oral drug designed to selectively inhibit PARP1 while largely sparing PARP2. Current PARP inhibitors such as olaparib inhibit both proteins, and suppression of PARP2 is thought […]
Tracking Response and Resistance to Lu-177 Plus Immunotherapy
/in Post-hoc/by MaxA new analysis of the PRINCE clinical trial suggests that combining blood-based ctDNA testing with PSMA PET could help identify which men with metastatic castration-resistant prostate cancer (mCRPC) are most likely to respond to Lu-177 PSMA plus immunotherapy. PRINCE was a multicentre Phase 1/2 trial involving 37 men with mCRPC. Patients received up to six […]
ctDNA Blood Test May Identify High-Risk mHSPC Before Treatment Begins
/in Clinical Trial, Metastatic/by MaxA blood test taken before starting treatment could help identify men with metastatic hormone-sensitive prostate cancer (mHSPC) who are at greater risk of developing treatment resistance early. We have already discussed the importance of ctDNA after treatment in a previous article, but this new study looks at its potential value even before treatment begins. A […]
Radium-223 May Reduce Immune Activity in Prostate Cancer Bone Metastases
/in Clinical Trial, Metastatic/by MaxA new prospective clinical study suggests that radium-223 may change the immune environment of prostate cancer bone metastases in a way that makes subsequent immunotherapy less effective. The study included 28 men with metastatic castration-resistant prostate cancer (mCRPC) and predominantly bone metastases. Patients received radium-223, with six injections planned at four-week intervals. Researchers wanted to […]
CEA Emerges as a Potential Prognostic Marker for Lu-177 PSMA Therapy
/in Observational/by MaxA simple blood test normally associated with colorectal cancer could provide additional information about how men with metastatic castration-resistant prostate cancer fare after 177Lu-PSMA-617 therapy. A new prospective study of 142 patients found that elevated carcinoembryonic antigen (CEA) before treatment was independently associated with shorter progression-free and overall survival. The finding does not mean that […]
Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR
/in Clinical Trial, Metastatic, Phase 1/by MaxA newly registered phase 1 trial is taking an interesting approach to one of the limitations of T-cell engagers in prostate cancer: rather than simply trying to make them more powerful, it will test whether a second immune signal can make their activity more durable. The trial will evaluate JANX007 together with the new drug […]